

Shasun acquires global rights for Ibuprofen extended release OTC & Nuprin brand

06 May 2014 | News | By BioSpectrum Bureau

Shasun acquires global rights for Ibuprofen extended release OTC & Nuprin brand



Shasun India, an integrated pharmaceutical company acquired global rights from ScolrPharma, USA to develop and commercialize Ibuprofen 12 hour Extended Release OTC tablets ("Asset") as well as associated Controlled Release Technology (CDT) and Nuprin trademark, a well-known brand in analgesics, through its wholly owned subsidiary, SVADS Holdings, Switzerland.

The Asset, having completed phase III successfully in the US, is a differentiated long acting NSAIDS in the multibillion dollar global OTC analgesic market. Shasun is the world's leading, vertically integrated manufacturer of Ibuprofen and its derivatives, from actives to formulated packaged products for both the Rx and OTC markets. This acquisition complements Shasun's strategy to expand its range of NSAIDS products through novel, safe and efficacious delivery technologies including transdermal applications across its Ibuprofen franchise.

Commenting on the acquisition, Mr S Abhaya Kumar, managing director, Shasun Pharmaceuticals Ltd said, "The acquisition is the first among a series of strategic initiatives in our quest to continue to enhance our global leadership in the NSAIDS category. Our commitment to reliable and affordable innovation across Ibuprofen franchise is not only focused on providing safer products which can enhance patient compliance but also provide a differentiated launch pad for Shasun's partnership in the OTC and Rx markets worldwide."